Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model.
about
Advances in Immunotherapy for Melanoma: A Comprehensive Review.Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3α-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons.Trial watch: DNA-based vaccines for oncological indicationsCombination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma
P2860
Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Fusion of the dendritic cell-t ...... val in a mouse melanoma model.
@en
Fusion of the dendritic cell-t ...... val in a mouse melanoma model.
@nl
type
label
Fusion of the dendritic cell-t ...... val in a mouse melanoma model.
@en
Fusion of the dendritic cell-t ...... val in a mouse melanoma model.
@nl
prefLabel
Fusion of the dendritic cell-t ...... val in a mouse melanoma model.
@en
Fusion of the dendritic cell-t ...... val in a mouse melanoma model.
@nl
P2093
P2860
P1476
Fusion of the dendritic cell-t ...... val in a mouse melanoma model.
@en
P2093
Arya Biragyn
Hong Zhang
James T Gordy
Richard B Markham
P2860
P2888
P356
10.1186/S40425-016-0189-Y
P577
2016-12-20T00:00:00Z
P6179
1002812818